In clinical trials, PARP inhibitors are mostly administered to cancer patients with homologous recombination repair deficiencies including those with breast and ovarian cancers carrying BRCA1 and BRCA2 mutations (gBRCA1/2m) and castration-resistant prostate cancer. This evidence concerns the gene PARP1 and ovarian cancer.